Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses
Open Access
- 15 March 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (6) , 2416-2426
- https://doi.org/10.1158/1078-0432.ccr-04-1380
Abstract
Purpose: Cancer vaccines targeting tumor-associated antigens are being investigated for the therapy of tumors. Numerous strategies, including the direct intratumoral (i.t.) vaccination route, have been examined. For tumors expressing carcinoembryonic antigen (CEA) as a model tumor-associated antigen, we previously designed poxviral vectors that contain the transgenes for CEA and a triad of T-cell costimulatory molecules, B7-1, intercellular adhesion molecule-1, (ICAM-1), and leukocyte function associated antigen-3 (LFA-3) (CEA/TRICOM). Two types of poxvirus vectors were developed: replication-competent recombinant vaccinia and replication-defective recombinant fowlpox. We have shown previously that a vaccine regimen composed of priming mice s.c. with recombinant vaccinia-CEA/TRICOM and boosting i.t. with recombinant fowlpox-CEA/TRICOM was superior to priming and boosting vaccinations using the conventional s.c. route in inducing T-cell responses specific for CEA. These studies also showed that CEA was needed to be present both in the vaccine and in the tumor for therapeutic effects. Experimental Design: To determine specific immune responses associated with vaccination-mediated tumor regression, CEA-transgenic mice bearing CEA+ tumors were vaccinated with the CEA/TRICOM s.c./i.t. regimen, and T-cell immune responses were assessed. Results: In CEA+ tumor-bearing mice vaccinated with the CEA/TRICOM s.c./i.t. regimen, T-cell responses could be detected not only to CEA encoded in vaccine vectors but also to other antigens expressed on the tumor itself: wild-type p53 and an endogenous retroviral epitope of gp70. Moreover, the magnitude of CD8+ T-cell immune responses to gp70 was far greater than that induced to CEA or p53. Finally, the predominant T-cell population infiltrating the regressing CEA+ tumor after therapy was specific for gp70. Conclusion: These studies show that the breadth and magnitude of antitumor immune cascades to multiple antigens could be critical in the therapy of established tumors.Keywords
This publication has 18 references indexed in Scilit:
- Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory MoleculesClinical Cancer Research, 2004
- Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)Gene Therapy, 2003
- Alterations in Fas Expression Are Characteristic of, But Not Solely Responsible for, Enhanced Metastatic CompetenceThe Journal of Immunology, 2003
- Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cellsEuropean Journal of Immunology, 2003
- Immunotherapy for murine K1735 melanoma: Combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulatorsCancer Gene Therapy, 2002
- Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancerCancer Gene Therapy, 2000
- MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeEuropean Journal of Immunology, 1999
- A wild‐type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cellsEuropean Journal of Immunology, 1996
- Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus VaccineJNCI Journal of the National Cancer Institute, 1992
- RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1992